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Cyanide is a toxic cytochrome c oxidase inhibitor that prevents the production of 
ATP, which consequently results in lactic acidosis, histotoxic hypoxia, and death. Dimethyl 
trisulfide (DMTS) is a promising sulfur donor (SD) type cyanide antidote that can react 
with cyanide to form the less toxic thiocyanate. These studies provide more insight into the 
characterization and biological effects for a newly formulated FF-DMTS compared to 
Poly80-DMTS. 
The first objective was to determine the optimal pH for rhodanese activity. This 
was determined by observing the SD efficiencies of DMTS and thiosulfate, without 
rhodanese and comparing that to their activity in the presence of rhodanese at a pH of 7.4, 
8.6, and 10.5. Post-reaction, the DMTS (3.5mM) was seen to be over 40x less concentrated 
than its TS counterpart (150mM), yet exceeds thiosulfate SD ability, supporting the idea 
that DMTS is a more efficient SD. 
Secondly, the in vitro blood brain barrier penetrability was determined using a 
Parallel Artificial Membrane Permeability Assay system. It was determined that the 
Poly80-DMTS (Papp =11.8x10
-6 cm/s) penetrated the blood brain barrier more than the FF-
DMTS (Papp=7.46x10
-6 cm/s), although the Poly80-DMTS (tlag=6.42 min.) had a lag time 
over 3x longer than FF-DMTS (tlag=2.00 min.). 
Thirdly, when analyzing the formation of methemoglobin by DMTS in vivo, FF-




of both formulations, however, produced less than 30% methemoglobin, which is the 
percentage that would induce methemoglobinemia and require medical assistance. 
Lastly, when observing the particle size distribution of the two formulations using 
the Zetasizer Nano, the particle size of FF-DMTS was almost 3.5x higher than that of the 
Poly80-DMTS. This can potentially be used to explain the slower blood brian barrier 
penetrability of FF-DMTS. 
The information obtained from these studies will be used for further 
characterization of DMTS as a cyanide antidote. Understanding how DMTS behaves in the 
body will give insight into developing an alternative cyanide therapeutic agent. The 
information from these studies, will contribute to the development of an intramuscular 
injector kit, which can potentially decrease the lives lost to cyanide intoxication. 
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Cyanide (CN), which represents both CN- and HCN, is an extremely toxic agent 
that can cause many detrimental effects after exposure. The severity of these effects is 
dependent on the concentration of CN that is present within the body. Since CN in the HCN 
form is a weak acid with a pka value of 9.2, then CN will predominantly exist as HCN at 
physiologic pH of 7.4.1 Due to the diminutive structure of the HCN molecule, it can 
penetrate many biological membranes, such as the blood-brain barrier and mitochondrial 
membranes. When CN enters the body, it binds to the terminal oxidase of the mitochondrial 
electron transport chain, also known as the cytochrome c oxidase, which ultimately leads 
to inhibition of oxygen utilization by the cells and eventually the inhibition of ATP 
production. When CN is present in the electron transport chain, it binds to the heme iron 
prosthetic group, Cytochrome a2+. This iron prosthetic group prevents the electrons from 
flowing from the Cytochrome a2+ to the Cytochrome a3
3+. This inhibition prevents the 
Cytochrome a3
3+ from utilizing O2, which suppresses the body’s aerobic metabolic 








Figure 1. Pathway for Cytochrome C Oxidase Inhibition by CN (reproduced with 
permission from St. Rosemary Education Institution).  
 
The suppression of the body’s aerobic metabolic pathway forces the body to utilize 
its anaerobic pathway, which causes the reduction of pyruvate to lactic acid, thus leading 
to lactic acidosis and histotoxic hypoxia.3 
 
Cyanide Utilization 
Since the 19th century, many countries have utilized CN as a conventional chemical 
warfare agent. French, Austrian, and German troops were some of the most notorious 
groups who have utilized CN as a warfare agent in the events such as World War I and II4 
Since then, its use has become more prevalent in contemporary society, especially in cases 
like the Jonestown Massacre in 1978 and the Tylenol poisonings in 1982. In addition to its 
use as a chemical warfare agent, CN has many industrial uses as well. CN is a significant 
factor in the production of many plastics and synthetic rubbers, as well as upholstery and 
insulations.3 The use of CN in these industries mean that individuals present during a house 
fire have a high chance of being exposed to toxic CN. Furthermore, it is also used in mining, 




Current Cyanide Antidotes 
Nithiodote™ and Cyanokit® are the two CN antidotes currently available for 
clinical use in the United States5. The active ingredients of Nithiodote™ are sodium nitrite 
and sodium thiosulfate (TS). Sodium nitrite converts the endogenous hemoglobin (Hb) to 
methemoglobin (MetHb), which has a high affinity for CN. MetHb proceeds to remove CN 
from the binuclear heme center of the cytochrome c oxidase and forms 
cyanomethemoglobin. TS, in the presence of rhodanese (Rh), reacts with CN to form the 
less toxic metabolite thiocyanate (SCN) that can be easily excreted from the body through 
urine.6 The Cyanokit® antidote contains hydroxycobalamin, which contains a cobalt metal 
center. Since CN has a high affinity to cobalt compounds, the hydroxycobalamin removes 
the CN from the cytochrome c oxidase and forms cyanocobalamin, which is also excreted 
from the body through urine.6 The drawback of these two antidotes is that both must be 
administered intravenously, which is very inconvenient when treating multiple individuals 
at once.7 Therefore, the development of an intramuscular injector kit would allow 
individuals to treat themselves, which dramatically increases the treatment efficiency for 
healthcare professionals. This idea is the primary inspiration for this research. 
 
Dimethyl Trisulfide (DMTS) 
Sulfane sulfurs and sulfur donors (SD) have been studied as CN antidotes as early 
as 1894 by S. Lang, where he reported TS as a CN antagonist.8 He describes how TS can 
readily combat CN intoxication by converting it to the less toxic SCN, which can be easily 
excreted through the body via urine. Since then, many other sulfur-containing compounds 




molecule that has become the center of investigation for discovering new CN therapies.5 
DMTS is a naturally occurring compound that can be found in many members of the Allium 
species, such as garlic and onions. DMTS is also responsible for 2.4% of garlic’s volatile 
components.9 Since members of the Allium species contain high amounts of sulfur, they 
possess a high propensity to serve as adequate SD in CN antagonism. Sulfur has a high 
affinity for CN and can form the less toxic SCN, which is considered the primary CN 
detoxifying mechanism in the body. Dr. Petrikovics et al., also observed that DMTS 
converts CN to SCN over 40 times more efficiently at a pH of 8.6 than that of the current 
CN antidote Nithiodote™, making DMTS as a potentially efficient CN therapeutic agent.5  
 
Rhodanese and Cyanide Reaction 
As aforementioned, Rh is a sulfurtransferase enzyme that catalyzes the conversion 
of CN to the less toxic SCN, due to the transfer of a sulfane sulfur atom. This reaction can 
be seen in Figure 2 below. 
𝐶𝑁− + 𝑆2𝑂3
2− → 𝑆𝑂3
2− + 𝑆𝐶𝑁− 
Figure 2. Conversion of CN to SCN.  
 
 The in vivo mechanism involves a double displacement reaction in which the sulfur atom 
of an appropriate SD such as TS (SSO3
2-) reacts with the free enzyme (E) to cleave the 
disulfide bond and forming a persulfide-substituted enzyme (ES). The ES then can interact 
with CN, which is a sulfur acceptor substrate to produce SCN.10 This process can be seen 





Figure 3. Mechanism of CN to SCN Catalysis by Rh. (Isom, G. E.; Borowitz, J. L.; 
Mukhopadhyay, S., Sulfurtransferase Enzymes Involved in Cyanide Metabolism. 
Comprehensive Toxicology, 2010, 485–500.) 
 
Optimal pH for Rh Activity 
The purpose of this experiment is to determine the SD efficacy of DMTS at the 
optimal pH for Rh activity. In order to do this, a modified version of Sörbo’s assay11 to 
colorimetrically determine the concentration of thiocyanate was used. The modified 
method was performed as described by Westley.12 For this assay, KCN, buffer solution, 
water, Rh (if used), and TS (or DMTS) and was added into a test tube. These buffers 
allowed the SD to react with the CN, under a particular pH, in the presence or absence of 
Rh. The addition of formaldehyde then stopped the reaction from continuing. Fe(NO3)3 
was then added to convert all SCN to Fe(SCN)2+. This red iron complex was then  measured 
spectrophotometrically to accurately determine the amount of SCN that was produced.  
The Blood-Brain Barrier (BBB) 
The BBB is a highly selective semipermeable membrane that divides the blood in 
the brain from the extracellular fluid of the central nervous system13. The BBB regulates 
the flow of many ions and cells between the blood and the brain. This flow of ions and 
cells is crucial for the body to maintain homeostasis. Concerning CN, the BBB is also 




Therefore, understanding the many types of pathways across the BBB is essential for the 
field of drug discovery and delivery.14 This highly regulated system possesses many routes 
for transport (Figure 4); however, for this study, the transcellular lipophilic pathway will 
be the route of interest. Most drugs enter the BBB by transcellular passive diffusion, due 
to the structure of the tight junctions and the limitations of the other pathways.15 Since 
DMTS is a very lipophilic compound, it can easily traverse the BBB through the 
transcellular lipophilic pathway. 
 
Figure 4. Pathways across the Blood-Brain Barrier (Reprinted by permission from:  
Springer Nature, Nature Reviews Neuroscience, Astrocyte–endothelial interactions at the 
blood–brain barrierArticle name, N. Joan Abbott et al, 2006) 
 
 
Parallel Artificial Membrane Permeability Assay (PAMPA) 
This study determines how quickly the various DMTS formulations can cross the 
BBB. The BBB penetrability of the Poly 80-DMTS formulation has already been 




the BBB penetrability by the FF-DMTS formulation to the previously measured Poly 80-
DMTS formulation. 
The PAMPA system is an artificially created cell membrane system that is widely 
used in the pharmaceutical industry as a permeability assay.15 These assays are critical for 
understanding the absorption of many drugs through various cellular membranes, including 
the BBB. First introduced by Kansy et al.,17 the PAMPA system consists of a lower donor 
plate and an upper acceptor plate. In between these two plates, there is a lipid layer acting 
as an artificially created membrane layer, which can be seen in Figure 5 below. 
 
Figure 5. Schematic of PAMPA Model  
 
The artificial membrane is typically formed by impregnating the filter bottom of the 
PAMPA plate with an organic solvent solution of lipids in order to simulate the cellular 
membranes of the body.18 For this particular study, a porcine lipid cocktail was used. Using 
this lipid cocktail is useful for mimicking the biological environment of the BBB, which 
allows for the measurement of DMTS penetrability.  
Many researchers in the field of drug discovery find the PAMPA system very beneficial 
due to its low cost, ease of automation, and simplicity. However, the limitations of the 




active transport pathway and a paracellular pathway.18 Thus, the PAMPA system can not 
completely simulate an actual biological membrane.  
 
Particle Size Distribution  
The purpose of this experiment is to characterize the particle size distribution of the 
FF-DMTS formulation in comparison to the previously determined Poly 80-DMTS 
formulation.19 Particle size is arguably one of the most important properties of particulate 
materials.20 This property is very essential in many industries because understanding the 
particle characterization can give more insight on a variety of characteristics such as 
dissolution rates, stability in suspensions, and viscosity. In order to characterize the FF-
DMTS formulation via particle size distribution, a Zetasizer Nano series was utilized. This 
instrument analyzes the sample via a process called dynamic light scattering. Dynamic 
light scattering, also known as photon correlation spectroscopy, measures the Brownian 
motion of the solution being analyzed and correlates that to the size of the particles in the 
solution. Dynamic light scattering is accomplished by directing a helium-neon laser at the 
sample and analyzing the intensity fluctuations of the scattered light.21 This scattered light 
is observed in a process called backscattering detection. For the Zetasizer Nano Series, the 
application of this process is made by a patented technique called Non-Invasive Back-
Scatter (NIBS). Since the backscatter is the property being measured, the laser does not 
have to go through the entire solution. NIBS minimizes the possibility of scattered light 





Figure 6. Non-Invasive Back Scatter Detection (Malvern Panalytical, Zetasizer Nano User 





The results from this measurement can be displayed in the form of number, volume, and 
intensity distributions, seen in Figure 7 below. 
 
Figure 7. Number, Volume, and Intensity Distributions (Malvern Panalytical, Zetasizer 
Nano User Manual,Malvern Panalytical, 2013. https://www.malvernpanalytical.com/en/ 
learn/knowledge-center/user-manuals/MAN0485EN).  
 
The number distributions display the results as peaks respective to the number of 
particles of a specific diameter. Volume distributions display the results as peaks respective 
to the volume of particles of a specific diameter. Lastly, intensity distributions display the 




diameter. All of these results give insight into the particle distribution and can be used to 
characterize many particulate materials. 
Methemoglobin Formation  
Recent studies described the affinity of DMTS to convert Hb to its oxidized form 
(MetHb) in vitro22 and in vivo23. In this process, the heme iron center in Hb is oxidized 
from its ferrous state to a ferric state (Figure 8).  
 
 
Figure 8. Structure for Hemoglobin and Methemoglobin.(Aintablian, H.; Kabbara, S., 
Carboxyhemoglobinemia and Methemoglobinemia in an Atypical Case of Salicylate 
Toxicity: A Potentially Hidden Association, Exploratory Research and Hypothesis in 
Medicine, 2017, 2(3), 72-76)  
 
Since the ferric state of the oxidized MetHb is unable to bind to oxygen, then this 
will ultimately hinder the body’s ability to transport oxygen to the rest of the body.24 
Although MetHb is unable to bind oxygen, it has a high affinity for CN. Therapeutic agents 
used to combat CN intoxication, such as NithiodoteTM, take advantage of this phenomenon 
and purposely induce MetHb formation in the body as a way to combat CN. The purpose 
of this study is to spectrophotometrically characterize the formation of MetHb by the FF-





formulation.25 The formation of MetHb by DMTS can potentially offer an alternative route 






Materials and Methods 
Chemicals  
The chemicals used in these experiments were DMTS, dimethyl disulfide (DMDS), 
potassium cyanide (KCN), sodium chloride, sodium hydroxide (NaOH), sodium 
bicarbonate, ferric nitrate (FeNO3), dimethyl sulfoxide (DMSO), heparin, potassium 
hexacyanoferrate(III), rhodanese, and 2,4,6-trimethylpyridine were all purchased from 
Sigma-Aldrich ((Milwaukee, WI, USA). TS, sodium nitrite, poly 80, and hydrochloric acid 
(HCl) were purchased from Alpha Aesar (Ward Hill, MA, USA). Acetonitrile (ACN), 
formaldehyde, and water were purchased from VWR (Radnor, PA, USA). Ethanol (EtOH) 
was purchased from Acros Organics (Thermo Fisher Scientific, Geel, Belgium). Glycine 
and sodium phosphate monobasic was purchased from JT Baker (Radnor, PA, USA). 
Prisma HT Buffer, Verapamil, and BSB were purchased from pION (Massachusetts, MA, 
USA). Sodium biphosphate dibasic were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA). Isofluorane was purchased from Piramal Enterprises Limited 
(Telegana, India). FF-DMTS and the FF-solvent was provided by the Southwest Research 
Institute (San Antonio, TX, USA). 
 
Animals 
For in vivo and ex vivo studies, male CD-1 mice were purchased from Charles River 
Laboratories (Charles River Laboratories, Inc., Wilmington, Massachusetts, USA). The 
climate-controlled room that housed the mice had a 12-hour light and a 12-hour dark 




with water and a 4% Rodent Chow that was purchased from Harlan Laboratories Inc. 
(Harlan Laboratories Inc., Indianapolis, Indiana, USA). All experiments involving the use 
of animal models were performed according to the guidelines delineated in the “Guide for 
the Care and Use of Laboratory Animals” and were performed in a facility accredited by 
the International Association for Assessment of Laboratory Animal Care (Frederick, 
Maryland, USA). After each study was completed, the surviving animals were terminated 
in accordance with the American Veterinary Medical Association Guidelines (American 
Veterinary Medical Association, Schaumburg, Illinois, USA). The Institutional Animal 
Care and Use Committee (IACUC) at Sam Houston State University in Huntsville, TX, 




All instruments used in these experiments were located in Dr. Ilona Petrikovics’s 
Lab at Sam Houston State University in Huntsville, TX. Table 1 below, delineates all the 












Analytical Instruments Employed in this Research 
Instrument Brand Model Number Location 
HPLC Thermo Scientific  Dionex Ultimate 3000 Dr. Petrikovics’s Lab 
GC-MS Agilent Technologies 7890A / 5975C Dr. Petrikovics’s Lab 
Zetasizer Nano Malvern Panalytical ZEN3600 Dr. Petrikovics’s Lab 
PAMPA System pIon Inc. FW5024 Dr. Petrikovics’s Lab 
Genesys 
Spectrophotometer 
Thermo Scientific GENESYS 10 UV Dr. Petrikovics’s Lab 
UV-Vis Scanning 
Spectrophotometer 
Schimadzu UV-2121 Dr. Petrikovics’s Lab 
Viscometer Brookfield Ametek DV3TLVCJ0 Dr. Petrikovics’s Lab 
 
Method for Optimal pH for Rh Activity Determination 
For this study, the SD activity of DMTS and TS was observed in vitro at three pH 
levels (7.4, 8.6, and 10.5) in the presence and absence of Rh. For the measurements at 
different pHs, different buffer solutions were used. The preparation of the different buffers 
is delineated below. 
Preparation of 10 mM Phosphate Buffer Solution (pH=7.4) 
  This phosphate-buffered saline solution was prepared by weighing 0.238 g of 
Na2HPO4 • 7 H2O, 0.19 g of NaH2PO4 • 1 H2O, and 8.0 g of NaCl into a 100 mL volumetric 
flask. DI water was then added just below the line, and the flask was inverted several times 
to ensure that everything was fully dissolved. Then, more DI was used to fill up the 
volumetric flask to the line. This solution was then transferred to a VWR glass storage 




meter, a 1 M NaOH solution, and 1 M HCl solution, the pH for this solution was then 
adjusted to a pH of 7.4.  
Preparation of 0.2 M Glycine-NaOH Buffer Solution (pH=8.6) 
 This glycine-NaOH buffer solution was prepared by weighing out 1.50 g  of 
glycine into a 100 mL volumetric flask. DI water was then added just below the line, and 
the flask was inverted several times to ensure that everything was fully dissolved. Then, 
more DI was used to fill up the volumetric flask to the line. This solution was labeled as 
“Solution A.” Next, 0.80 g of NaOH was weighed into another 100 mL volumetric flask 
and prepared similarly to Solution A. This solution was then labeled as “Solution B.” 
Lastly, 25 mL of Solution A and 22.75 mL of Solution B was added into a third, 100 mL 
volumetric flask, and dilute to the line with DI water, making the final glycine-NaOH 
buffer solution. This solution was then transferred to a VWR glass storage bottle and 
labeled as “Glycine-NaOH Buffer.” Using a Thermo Scientific Orion Star A211 pH meter, 
NaOH solution (1M), or HCl solution (1M), the pH for this solution was then adjusted to 
a pH of 8.6. 
Preparation of 0.2 M Carbonate Buffer Solution (pH=10.5) 
 To make this carbonate buffer, 0.84 g of NaHCO3 was weighed into a 100 mL 
volumetric flask and prepared as aforementioned. This solution was labeled as “Solution 
C.”  Next, 2.86 g of anhydrous Na2CO3 was weighed into another 100 mL volumetric flask 
and also prepared as aforementioned. This solution was then labeled “Solution D.” Lastly, 
20 mL of Solution C and 80 mL of Solution D was added into a VWR glass storage bottle 




NaOH solution (1M), or HCl solution (1M), the pH for this solution was then adjusted to 
a pH of 10.5. 
 Preparation of 100 U/mL Rh Solutions 
 To make the Rh solutions, 1 mg (100 U/mg)  of Rh was weighed into three 1.5 mL 
amber Eppendorf tubes. Into one tube, 1 mL of the phosphate buffer (pH=7.4) was added. 
This solution was then hand vortexed until fully dissolved and labeled appropriately. This 
process was then repeated for the glycine-NaOH (pH=8.6) buffer and the carbonate 
(pH=10.5) buffer and stored at 4 ̊C. 
To begin the experiment, the following solutions were added sequentially into a 
16x125 mm test tube: 
1. 390 µL of DI water 
2. 200 µL of buffer solution 
3. 10 µL Rh or DI water  
4. 200 µL of SD (3.5 mM DMTS, 150 mM TS, or neither) 
5. 200 µL of 250 mM KCN 
Total volume: 1000 µL.  
 
For the measurement of the blank, the addition of a SD was excluded and replaced by DI 
water. Once the solutions were pipetted, the test tubes were sealed by using Parafilm, hand 
vortexed for 10 seconds, and incubated at room temperature for one minute. Immediately 
after the one minute incubation period, the following solutions were added to the test tube: 
1. 500 µL of a 15% formaldehyde solution  
2. 1500 µL of 40 mM Fe(NO3)3 solution 
Once these solutions were added, they were again sealed with Parafilm and hand vortexed 
for 10 seconds. After being hand vortexed, 1000 µL of the final solution was measured 
spectrophotometrically at 460 nm using a plastic polystyrene (PS) cuvette.  





Figure 9. Detailed Schematic of the Rh Study Protocol 
 
Fe(SCN)2+ Calibration Curve 
 To create a calibration curve for Fe(SCN)2+, twelve caliber solutions were 
prepared, ranging between 0.0 mM  - 2.0 mM Fe(SCN)2+. In order to prepare these calibers, 
a 0.25 M Fe(SCN)2+ was  made by combining a 0.5 M Fe(NO3)3 solution, and a 1.5 M 
KSCN solution. These solutions were prepared as follows:  
 Preparation of a 0.5 M Fe(NO3)3 Solution 
 Into a 10 mL volumetric flask, 1.210 g of Fe(NO3)3 ● 9 H2O was added and filled 
to the marked line with DI water. This solution was then inverted several times until it was 
completely dissolved.  
 Preparation of a 1.5 M KSCN Solution 
 Similarly, to the previous solution, 1.460 g of KSCN weighed out and placed into 
a 10 mL volumetric flask. This solution was then diluted to the mark using DI water. The 
flask was then inverted several times until fully dissolved. 




To prepare this solution, 10 mL of the 0.5 M Fe(NO3)3 solution and 10 mL of the 1.5 KSCN 
solution were added to a 20 mL glass vial. This vial was then capped and hand vortexed 
for one minute.  
 Preparation of a 2.5 mM Fe(SCN)2+ Stock Solution  
 To prepare this solution, 200 µL of the 0.25 M Fe(NO3)3 solution and 19.8 mL of 
DI water were added to a 20 mL glass vial. This vial was then capped and hand vortexed 
for one minute or until fully mixed. After using the hand vortex, the vial was then labeled 
appropriately. This solution was then used to prepare the twelve caliber solutions.  
 Preparation of Twelve Caliber Solutions 
 Using the previously made 2.5 mM Fe(NO3)3 Stock Solution, twelve caliber 
solutions were made into 1.5 mL plastic PS cuvettes with concentrations of 0, 0.005, 0.025, 
0.05, 0.10, 0.25, 0.50, 0.75, 1.0, 1.25, 1.50, 1.75, and 2.0 mM. These solutions were made 
by using the dilution equation below, where C1 is the initial concentration of 2.5 mM 
Fe(NO3)3, V1 is the volume (µL) of stock solution needed, C2 is the target concentration, 
and V2 is the final volume of 1000 µL. 
𝐶1𝑉1 = 𝐶2𝑉2 
Figure 9. Dilution Equation  
 
 
Once all the twelve caliber solutions were made, they were measured 
spectrophotometrically at 460 nm and used to create a calibration curve. For these 





Method for BBB Penetration by FF-DMTS and Poly 80-DMTS  
 For this PAMPA method, the 96-well polyvinylidene membrane microplates with 
pre-loaded magnetic stirrers were impregnated with 2% porcine brain lipid following the 
instructions delineated in the Pion PAMPA Instruction Manual (REF). For the PAMPA 
study using the FF-DMTS formulation, 90 µL of the 10 mg/mL FF-DMTS stock solution 
was diluted with 8.91 mL of diluted Prisma HT Buffer. This Prisma HT Buffer solution 
was previously set to a pH of 7.4 using 1.0 M NaOH and a Thermo Scientific Orion Star 
A211 pH meter. 180 µL of the resulting 0.1 mg/mL FF-DMTS in Prisma HT Buffer 
solution was pipetted into three wells on the donor plate. Following this, the acceptor plate 
was carefully mounted onto the donor plate, ensuring that no air gets in between the donor 
plate and the lipid membrane on the acceptor plate. Then, 200 µL of the FF-DMTS in Brain 
Sink Buffer (BSB) solution was pipetted into the corresponding acceptor wells. This FF-
DMTS-BSB solution was prepared by diluting 200 µL of the vehicle for FF-DMTS  (FF-
solvent) with 19.8 mL of BSB concentrate. Once the FF-DMTS-BSB solution was pipetted 
into the acceptor plate, it was then sealed using the PAMPA sealing tape. The PAMPA 
sandwich was then carefully placed into the GutBox, the thickness of the aqueous boundary 
layer was set to 40 µm, and the sponges were saturated with deionized water. The GutBox 
was then turned on, and the PAMPA plate was allowed to incubate for a total of 90 minutes. 
Once the GutBox was started, 200 µL of the solution was extracted from the acceptor plate 
every 30 minutes. After each extraction, 200 µL of the FF-solvent was then pipetted back 
into the acceptor plate. The extracted samples were then analyzed using the HPLC. 
To prepare the solutions for HPLC analysis, glass inserts were first placed into 




the first insert along with 40 µL of the extracted solution. This vial was then sealed and 
placed into the HPLC for analysis. These same steps were repeated for the 0, 30, 60, and 
90-minute samples.  
Table 2 










100 µg/mL DMTS and FF 
solvent  
in Prisma HT buffer 
0, 90 
Brain Sink Buffer  
Solution + FF solvent 
30, 60, 90 
50 µM Verapamil in DMSO + 
FF solvent (Solution  
in Prisma HT buffer) 
0, 90 
Brain Sink Buffer  
Solution + FF solvent 
90 
50 µM Verapamil in DMSO 
in Prisma HT buffer 
0, 90 




Method for Particle Size Distribution Comparison of FF-DMTS and Poly 80-DMTS 
 For this experiment, the Poly 80-DMTS formulation (50 mg DMTS /15% Poly80 
mL) was prepared according to the protocol patented by the Petrikovics’s lab 
(US20150297535, 2015).  
Preparation of the 15% Poly 80 Solution 
Using an analytical balance, 3 g of Poly 80 was pipetted into a 20 mL glass vial. To 
this vial, HPLC-grade water was added until the scale read 20 g. A stir bar was then added 
to the vial, and the vial was sealed using a rubber cap. This vial was then allowed to stir 




hand-shaken until the Poly 80 was fully dissolved. Once it was fully dissolved, the vial was 
labeled appropriately and stored at 4 °C overnight.  
Preparation of the 50 mg/mL DMTS in 15% Poly 80 Solution 
The previously prepared 15% Poly 80 solution was removed from the fridge and 
left at room temperature for approximately 30 minutes. To prepare the 50 mg/mL DMTS 
solution, 500 mg of DMTS was pipetted into a 10 mL volumetric flask. Then, the 15% 
Poly 80 solution was added to the volumetric flask until it reached the marked line. The 
volumetric flask was capped and hand vortexed for approximately 5 minutes. The solution 
was transferred to a 10 mL glass vial and crimp sealed. This solution was then auto 
vortexed at maximum speed for approximately 30 minutes, followed by handshaking for 
another 10 minutes. Once that was completed, the vial was labeled appropriately and stored 
at 4 °C overnight. 
To run this experiment, the Zetasizer Nano was turned on and allowed to warm up 
for approximately one hour. Then, the Standard Operating Procedure (SOP) parameters for 
the measurement of the Poly 80-DMTS solution and the FF-DMTS solution were each 
created using the following method. Under the “Sample” tab, the sample name and any 
notes were listed. Below this tab, there was the “Material” tab. This section is where 
DMTS, which has a refractive index of 1.602 and an absorption value of 0.001, was 
entered. Next, the Dispersant for the Poly 80-DMTS formulation was selected to be the 
15% Poly 80 Solution. Since the temperature, viscosity, and refractive index were needed 
for this portion, 25 °C, 2.270, and 1.350 were entered, respectively. Alternatively, for the 
Dispersant for the FF-DMTS formulation, the 10% Aqueous Vehicle was selected. Instead 




and a refractive index of 1.367. Once the values of the Dispersant were entered, the 
Temperature and Equilibration time was entered as 25 °C for 30 seconds in the 
“Temperature” tab. Lastly, Under the “Measurement” tab, a 173° Backscatter was selected 
as the measurement angle with three measurements and 0 seconds between each 
measurement. All other parameters remained unaltered from the default settings.  
After the SOP for each sample measurement was loaded, 1000 µL of the sample 
was pipetted into a PS cuvette so that the sample depth remained between 10 mm and 15 
mm from the bottom of the cuvette. The cuvette was then placed into the sample 
compartment and measured. 
 
Method for In Vivo Methemoglobin (MetHb) Formation by DMTS Formulations 
Prior to the start of this experiment, the following solutions were prepared: 500 
U/mL heparin solution, 5% (m/v) K3Fe(CN)6, 0.675% (v/v) Colloidine Buffer, and a 5% 
(m/v) KCN. A detailed protocol for the preparation of these solutions can be seen below: 
500 U/mL Heparin Solution 
Using an analytical scale, 13.85 mg of heparin was added to a 5 mL glass vial. To 
this, 5 mL of DI water was added, and the vial was crimp sealed. The sealed vial was then 
left on the auto vortex at max speed until heparin was fully dissolved. This solution was 
then labeled and kept at 4°C until further use. 
5% (m/v) K3Fe(CN)6 Solution 
Using an analytical scale, 250 mg of solid K3Fe(CN)6 was added to a 5 mL glass 




was wrapped in foil and left on the auto vortex at max speed until everything was fully 
dissolved. This solution was labeled and kept at room temperature until further use.  
0.675% (v/v) Colloidine Buffer Solution 
Into a 500 mL volumetric flask, approximately 400 mL of sonicated DI water was 
added. To this, 3.375 mL of 2,4,6-trimethylpyridine and 1.75 mL of HCl was added. Then, 
using more DI water, the flask was filled until the meniscus reached the marked line. This 
solution was inverted several times until fully mixed and transferred to a VWR glass 
storage container. This solution was then labeled and kept at 4°C until further use. 
5% (m/v) KCN Solution 
The preparation of the KCN solution was done completely under a fume hood to 
ensure proper safety protocols. Also, the wearing of thick rubber gloves, goggles, and a lab 
coat was strictly enforced for this preparation. First, the desiccator containing the solid 
KCN salt was brought into the fume hood as well as the analytical scale and the hand 
vortex. Then, 1.250 g of the KCN salt was weighed and added into a 25 mL volumetric 
flask. To this flask, 25 mL of DI water was added until the meniscus reached the marked 
line. The flask was then capped, sealed with Parafilm, and hand vortexed until the KCN 
was fully dissolved. Once dissolved, the KCN solution was transferred into three, 10 mL 
glass vials and crimp sealed. These solutions were then labeled and kept at room 
temperature until further use.  
 
 Mice Injection by the FF-DMTS Formulation 
These animal studies were conducted in accordance with the guidelines of The 




accredited by AAALAC (American Association for the Assessment and Accreditation of 
Laboratory Animal Care, International). At the end of the experiment, all remaining 
animals were euthanized in accordance with the AVMA Guidelines for the Euthanasia of 
Animals: 2013 Edition (AVMA Guidelines). The Institutional Animal Care and Use 
Committee (IACUC) permission number is 15-09-14-1015-3-01.  
Once these solutions were prepared, a pre-weighed CD-1 male mouse was then 
injected with the FF-DMTS formulation into the right thigh muscle. The injection volume 
was calculated using the following equation below. 




) ∗ 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)




Figure 10. Equation Used to Calculate Injection Volume. 
 
When the injection volumes exceeded the 50 µL injection per injection site limit, the 
solution was divided and was injected into two legs. After injection, the mice were  allowed 
to incubate for their designated incubation times. Approximately 4 minutes before the end 
of the incubation period, the mice were anesthetized using isoflurane, and their chest cavity 
was exposed. Once the incubation period was complete, blood was drawn directly from 
their heart, using a heparinized syringe, and transferred to a heparinized 5 mL glass vial. 
0.2 mL of this blood was transferred to a 10 mL glass vial, and 5 mL of DI water was 
added. This solution was auto vortexed for 1 minute at 2000 RPM. To this, 5 mL of the 
0.675% (v/v) colloidine buffer was added, and the solution was auto vortexed again. This 
solution was then transferred into nine different 1.5 mL amber Eppendorf tubes and 
centrifuged for three minutes at 4 °C and 10000g. The supernatant from these vials was 




pipetted into two separate 10 mL glass test tubes. To test tube1, 50 µL of the 5% (m/v) 
K3Fe(CN)6 solution was added, and to the test tube 2, 50 µL of DI water was added. These 
test tubes were then mixed thoroughly. Using a 1000 µL pipette, each test tube was divided 
evenly into two 3 mL plastic PS cuvettes. Into two cuvettes (one from the 5% (m/v) 
K3Fe(CN)6 test tube and one from the DI water test tube), 50 µL of DI water was added. 
To the remaining two test cuvettes, 50 µL of the 5% KCN solution was added. Immediately 
after each addition, the cuvettes were covered with Parafilm, mixed by inversion for about 
five times, and left to incubate at room temperature for 5 minutes. After the incubation 
period, the absorbance of each cuvette was measured spectrophotometrically at 630 nm. A 







Results and Discussion 
Optimal pH for Rh Activity Determination 
In order to determine the optimal pH for Rh activity, SDs TS and DMTS were 
monitored in vitro at a pH of 7.4, 8.6, and 10.5 with and without Rh. These specific pH 
values were tested since 7.4 is the physiological pH of the human body, and pHs 8.6 and 
10.5 have been reported to be the optimal pH for Rh activity.11,26,27  
To observe the enzymatic conversion of CN to SCN at all pH values, the three 
different buffers were used with Rh. To observe the spontaneous conversion of CN to SCN, 
the 7.4 Glycine-NaOH buffer was used without Rh. Using a concentration of 150 mM TS 
and 3.5 mM DMTS, the correlation between TS and DMTS SD activity both in the 
presence and absence of Rh was determined.  
 
Figure 11. Fe(SCN)2+ Formation with Rh (left) and without Rh (right) with SDs DMTS 
and TS. Note: Concentrations for SDs represent the total concentration in solution after 





After the SDs were able to react with the CN to form SCN, they were then treated 
with Fe(NO3)3 to form the metal complex Fe(SCN)
2+. This metal complex was measured 
spectrophotometrically at 460 nm to determine the amount of SCN formed. 
It can be seen in Figure 11 that DMTS produced more SCN than TS, both in the 
presence and absence of Rh. For Rh at pHs of 7.4, 8.6, and 10.5, the concentrations of 
Fe(SCN)2+ produced from the 3.5 mM DMTS solution were approximately 1.30, 1.30, and 
0.60 mM, respectively. For TS, the concentrations of Fe(SCN)2+ was significantly lower. 
For Rh at pHs 7.4, 8.6, and 10.5, the concentrations of Fe(SCN)2+ from 150 mM TS were 
0.50, 0.80, and 0.40 mM, respectively. Without Rh, tested at a pH of 7.4, the 3.5 mM 
DMTS solution produced approximately 0.60 mM of Fe(SCN)2+, and the 150 mM TS 
solution produced approximately 0.40 mM of Fe(SCN)2+. 
More importantly, the concentration of DMTS can be seen to be over 40 times less 
concentrated than its TS counterpart. This supports the idea that DMTS is a much more 
efficient SD than TS. In the case of the optimal pH for Rh activity, it can be seen that SCN 
is produced in the highest concentrations at a pH of 8.6 for DMTS and TS. Although the 
SCN formation for DMTS is comparable at a pH of 7.4 and 8.6, this can be attributed to 
the spontaneous formation of SCN without the use of the sulfurtransferase enzyme. In the 
case of TS, SCN concentrations reached a maximum at a pH of 8.6. These concentrations 
can be attributed to TS’s dependence on Rh for the conversion of CN to form SCN. Since 
SCN concentrations reached a maximum at the pH of 8.6, it suggests that the optimum pH 
for Rh activity is near 8.6.  
To further support these claims, a calibration curve using SCN at concentrations of 




the data is represented as an average of three measurements with their corresponding 
standard deviations. Some error bars may not be visible due to their very low standard 
deviation. 
 
Figure 12. Calibration Curve for SCN at 460 nm.  
 
The resulting calibration curve (Figure 12) shows a linear plot with an R2 of 0.9888 
and an equation of y = 0.981x-0.404. For this calibration curve, the limit of detection 
(LOD) and the limit of quantitation (LOQ) were determined using the equations below.  
LOD = 3s / m = (3 × 0.0029) / 0.981 = 0.009 mM 
LOQ = 10s / m = (10 × 0.0029) / 0.981 = 0.029 mM 
For these calculations, m is the slope and s is the standard deviation of the least 
concentrated caliber solution, which was calculated using the equation below. 
𝑠 =  √








In addition, the accuracy and precision percentage values were also calculated using the 
equations below: 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (%) =
𝑥 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 − 𝑥 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑
𝑥 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑
∗  100 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%) =
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝑀𝑒𝑎𝑛 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
∗  100 
Figure 13. Equations Used to Calculate Accuracy and Precision.  
 
The calculated values for accuracy and precision can be seen in Table 3. 
Table 3 
Accuracy and Precision for SCN Calibration Curve 
[SCN] (mM) Accuracy (%) Precision (%) 
0.50 -5.7 2.5 
0.58 -0.2 1.4 
0.67 3.0 0.9 
0.75 4.0 0.7 
0.92 1.8 2.3 
1.00 -0.9 0.4 
1.04 -2.0 0.8 
 
Blood-Brain Barrier Penetration by FF-DMTS and Poly 80-DMTS 
  The PAMPA system is a widely used method that measures the membrane 
penetration of various drugs through a model membrane. For this experiment, the clearance 
volume (Cvol), lag time (tlag), and the apparent permeability (Papp) of the FF-DMTS 
formulation were determined and compared to the values obtained previously for the Poly 




Understanding the Cvol, which can be defined as the amount of DMTS filtered out 
of the blood and into the BBB over time, can be highly advantageous in the analysis of 
transmembrane diffusion. For this study, the Cvol of the FF-DMTS formulation was 
determined at the time intervals of 30, 60, and 90 minutes (Figure 4). Compared to the Poly 
80-DMTS formulation, which had an average Cvol of 4.998, 11.358, and 17.718 µL for the 
respective 30, 60, and 90-minute time points, the FF-DMTS formulation had a relatively 
slower clearance rate (Table 4).  
Table 4 
Clearance of FF-DMTS 
Time (min.) Cvol (µL) Average Standard Deviation 
30 4.16 3.46 1.18 
 2.26   
 3.96   
60 9.11 7.44 1.57 
 5.99   
 7.22   
90 14.79 11.28 3.05 
 9.74   







Figure 14. Clearance for PAMPA Study with FF-DMTS. Each data point represents the 
average of three measurements plus or minus the standard deviation (n=3)  
 
 
Based on this information, the tlag for the FF-DMTS formulation was determined to be 2.00 
minutes. The tlag is defined as the finite time taken for DMTS to appear within the acceptor 
portion of the PAMPA plate.17 Compared to the tlag of the Poly 80-DMTS formulation, 
which has a tlag of 6.42 minutes, the FF-DMTS appears in the acceptor plate nearly three 
times quicker. 
Lastly, the Poly 80-DMTS formulation was found to have a Papp of  
11.8x10-6 cm/s. Based on these experiments, the Papp for FF-DMTS was found to be 
7.46x10-6 cm/s, which is six times lower than that of the Poly 80-DMTS formulation. 
 The Papp was calculated using the equation below. 
𝑃𝑎𝑝𝑝 =
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑎𝑐𝑐𝑒𝑝𝑡𝑜𝑟(𝑚𝐿) ∗ 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑐𝑐𝑒𝑝𝑡𝑜𝑟𝛥𝑡(
µ𝑔
𝑚𝐿)









The Papp of each triplicate measurement was calculated using this equation, and the reported 
Papp represents the average of each Papp value. The standard deviation for this was 
determined to be 2.25x10-6 cm/s. To obtain the values for the concentration of DMTS in 
the acceptor plate, which was needed for Papp calculations, a calibration curve (Figure 16) 
was created. For this calibration curve, DMDS was used as an internal standard. Values for 
cvol for the FF-DMTS formulation are denoted as an average plus minus the standard 
deviation (n=3). The standard deviation for the Poly 80-DMTS formulation was not 
















































Clearance Volume, Lag Time, and Apparent Permeability of FF-DMTS and Poly 80-DMTS 
Formulations 
 Poly 80-DMTS* FF-DMTS 
Clearance Volume (Cvol)   
          30 minutes 5.0 µL/min 3.6 ± 1.2 µL/min 
          60 minutes 11.0 µL/min 7.4 ± 1.6 µL/min 
          90 minutes 18.0 µL/min 11.0 ± 3.0 µL/min 
Lag Time (tlag) 2.05 min. 2.00 min. 
Apparent Permeability (Papp) 12.0x10
-6 cm/s 7.5x10-6 cm/s 
Note. Values for Cvol are denoted as averages (n=3). *Standard deviations for Poly 80-
DMTS were not provided from the reference article16.  
 
Particle Size Distribution Comparison of FF-DMTS and Poly 80-DMTS 
Based on the volume distributions for the FF-DMTS formulation and the 
Poly 80-DMTS formulation, the particle size of the FF-DMTS is over 3.5x higher than that 
of the Poly 80-DMTS formulation. For the Poly 80-DMTS formulation, a particle size with 
a diameter of 4.275 nm contributed to 100% of the light scattered. Conversely, for the FF-
DMTS formulation, a particle size with a diameter of 15.77 nm contributed to 99.0% of 
the total light scattered. Based on these volume distributions, we can determine that the 
FF-DMTS formulation produces bigger micelles compared to the Poly 80-DMTS 
formulation, which can explain why the Poly 80-DMTS formulation has a higher Papp than 






Figure 17. Size Distribution by Volume for 50 mg/mL Poly 80-DMTS formulation.  
 
Figure 18. Size Distribution by Intensity for 100 mg/mL FF-DMTS formulation.  
  
In Vivo Methemoglobin Formation by DMTS Formulations 
The purpose of this study is to characterize the in vivo MetHb formation by the FF-
DMTS in vivo on a mice model and compare it to the results of the previously published 
Poly 80-DMTS formulation.22 Recent experiments show the relationship between the 
DMTS dose and MetHb formation. The FF-DMTS formulation was injected via 
intramuscular injection (IM) into CD-1 male mice (15-30 g) at several doses and sampling 
times. The doses applied were 25, 100, 175, 220, 277, and 349 mg/kg with sampling times 




The data sets for MetHb formation were split into two sets: a low dose, and a high 
dose. The “low dose” data set (Figure 19) includes doses of 25, 100, and 175 mg/kg which 
were injected into one leg, while the “high dose” data set (Figure 20) consisted of doses 
220, 277, and 349 mg/kg, which were injected into two legs. 
 
Figure 19. “Low Dose” Data Set for MetHb Formation after IM Injection of FF-DMTS 







Figure 20. “High Dose” Data Set for MetHb Formation after IM injection of FF-DMTS 
with sampling times of 5, 10, 20, 30, and 60 minutes. 
For the “low dose,” the highest percentage of MetHb formed was 14.32%, which was seen 
at 20 minutes for the 175 mg/kg FF-DMTS dose. This was followed by the 100 mg/kg FF-
DMTS dose at 30 minutes with a MetHb percentage of 8.56% and the 25 mg/kg FF-DMTS 
dose at 30 minutes with a MetHb percentage 2.2%. The time of maximum concentration 
(tmax) and maximum concentration (cmax) are directly proportional to the FF-DMTS dose 
(Table 6).  
For the “high dose,” the highest percentage of MetHb formed, which was 11.8%, was 
surprisingly seen in the 277 mg/kg FF-DMTS dose at 20 minutes. This was then followed 
by the 11.13% formed at 30 minutes for the 220 mg/kg FF-DMTS, and the 8.7% formed 









MethHb Formation Evaluation of FF-DMTS after IM Injection in a Mice Model 
FF-DMTS Dose cmax tmax 
25 mg/kg 2.24 % 20 minutes 
100 mg/kg 8.56 % 30 minutes 
175 mg/kg 14.32 % 30 minutes 
220 mg/kg 11.13 % 30 minutes 
277 mg/kg 11.84 % 20 minutes 
349 mg/kg 8.65 % 20 minutes 
   
Table 7 
MethHb Formation Evaluation of Poly 80-DMTS after IM Injection in a Mice Model 
Poly 80- DMTS Dose cmax tmax 
50 mg/kg 3.28 % 20 minutes 
100 mg/kg 6.12 % 25 minutes 
200 mg/kg 9.69 % 25 minutes 
250 mg/kg 10.76 % 30 minutes 
 
An initial hypothesis expected a positive correlation between the FF-DMTS dose injected 
IM and the % MetHb formed. The “low dose” data set supports this hypothesis; however, 
the %MetHb formed in the “high dose” data set is relatively lower than expected. A 
potential cause for this result could be due to the multiple injections needed to reach the 
required “high doses.” Since these injection volumes calculated for this experiment 
exceeded the allowed 50 µL per injection site, therefore they were divided into two separate 
injections into two legs. This process could potentially affect the absorption rate, thus 




minutes post-injection. These seizures present an additional factor in affecting the 
absorption rate of DMTS.  
When compared to its Poly 80-DMTS counterpart (Table 7) the FF-DMTS 
formulation produced more MetHb per dose. After a 10-minute incubation period, the 
%MetHb formation for the 50, 100, 200 and 250 mg/kg doses for Poly 80-DMTS were 
2.63, 4.50, 6.69 and 7.85%, respectively. The highest %MetHb formation (3.28, 6.12, 9.69 
and 10.76% MetHb) was observed at 20, 25, 25 and 30 min., following IM injection of 50, 
100, 200 and 250 mg/kg Poly 80-DMTS, respectively.  
The production of MetHb is an important secondary antidotal pathway for DMTS, so 
observing this is vital for developing a useful therapeutic agent. In these studies, the 
formation of MetHb from both formulations was shown to be just below the levels that 
would require medical intervention. Neither of the formulations at the observed doses 
produced a cmax higher than 30%, which is the percentage of MetHb in the body that would 








CN is a toxic cytochrome c oxidase inhibitor that prevents the production of ATP, 
which can result in many toxic effects such as lactic acidosis and death. DMTS is a 
promising SD type cyanide antidote that can react with CN to form the less toxic SCN. 
These studies serve to provide more insight on the characterization and biological effects 
of FF-DMTS as compared to Poly 80-DMTS. These two formulations are  characterized 
using various analytical methods as described above.  
In conclusion, when comparing the SD efficiencies between DMTS and TS at 
various pH values, in the presence and absence of Rh, it was determined that DMTS is a 
much more effective than TS, thus making it a prospective CN antidote alternative. In 
addition, when comparing the BBB penetrability of the two DMTS formulations in vitro 
using the PAMPA system, it was determined that the Poly 80-DMTS formulation 
(Papp=12.0x10
-6 cm/s) penetrated the BBB slightly faster than the FF-DMTS formulation 
(Papp=7.5x10
-6 cm/s).  
Next, when analyzing the formation of methemoglobin by DMTS over time in 
vivo using CD-1 male mice models, the FF-DMTS produced significantly more MetHb 
than its Poly 80-DMTS counterpart. Up to the FF-DMTS dose of 175 mg/kg, which had 
the highest amount of MetHb formed (14% MetHb), there was a linear trend that was 
synonymous with the Poly 80-DMTS trend, which had the highest amount of MetHb 
formed (10% MetHb) at the 250 mg/kg dose. Although, FF-DMTS produced much more 
MetHb, both formulations produced less than 30% MetHb, which is the percentage of 




Lastly, when observing the particle size distribution of the two formulations using 
dynamic light scattering, the particle size of the FF-DMTS was over 3.5 times higher than 
that of the Poly 80-DMTS formulation, which can explain the slower BBB penetrability 
of the FF-DMTS formulation.  
These data and information obtained from these studies will be used for further 
understanding of the antidotal effects of DMTS. Understanding how DMTS behaves in 
the body will give more insight into developing an adequate CN therapeutic agent 
alternative. By obtaining the information from these studies, we will be closer to 
developing an intramuscular injector kit. This approach can potentially decrease the lives 
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Figure A1. Schematic for MetHb Study Protocol
SwRI formulated DMTS (FF-DMTS) 
• Doses for IM injections: 25, 100, 175, 220, 277, and 349 
mg/kg 
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